Head of Multiple Myeloma & AML, Oncology - Global Patient Safety
Posted Sep 1, 2026 · We last checked this listing on Oct 6, 2026
Likely interview questions for this role
Written from this job description, not a generic list. Each one notes what the interviewer is really checking.
About your past
This role leads product safety teams for multiple myeloma and acute myeloid leukemia and manages medical directors up to executive level. Walk me through leading a product safety team.
What they are checking: Whether they can lead senior physicians in safety work, setting direction and standards while respecting their expertise and independence.
You'd manage medical directors at several levels. How do you develop a medical director into a safety leader?
What they are checking: Whether they can grow medical directors into safety leaders, building judgment, communication and confidence to defend positions with regulators.
How do you communicate a complex safety interpretation to a cross-functional team that wants a simple answer?
What they are checking: Whether they can make safety findings clear without oversimplifying, so cross-functional teams act correctly instead of hearing only what they want.
What would you do
A safety finding would change a product's label and the commercial impact would be significant. How do you handle that?
What they are checking: Whether they keep safety conclusions independent of commercial pressure, because patients and regulators depend on safety teams following the evidence.
This is based at North Chicago within global patient safety, covering two hematologic malignancies. What would you want to know about the portfolio and the team before you took it?
What they are checking: Whether they ask about the portfolio, open signals and team strength before accepting, showing they understand the weight of the role.
About the work
You'd set strategy for pharmacovigilance documents including medical safety assessments and regulatory responses. How do you approach a safety assessment on an emerging signal?
What they are checking: Whether they approach an emerging signal with a clear, structured method, since safety assessments shape labels, regulators' views and patient protection.
You'd analyze and interpret aggregate safety data. What makes you conclude that an observed pattern is a real safety signal?
What they are checking: Whether they apply rigorous criteria like strength, consistency and biological plausibility before calling a pattern real, avoiding both false alarms and missed risks.
Oncology patients are seriously ill and treatments are toxic by design. How do you assess causality against that background?
What they are checking: Whether they can separate drug effects from disease and other treatments in very sick patients, which is the hardest judgment in oncology safety.
You'd have oversight of periodic reports. What separates a good periodic safety report from a compliant one?
What they are checking: Whether they see periodic reports as real scientific analysis, not only a regulatory filing, since good reports reveal what the data actually means.
The posting names applying pharmacology, chemistry and non-clinical toxicology to safety surveillance. How do you use preclinical data when a clinical signal appears?
What they are checking: Whether they combine preclinical and clinical evidence when assessing a signal, using mechanism and toxicology to judge whether a finding is plausible.
Practice this interview out loud.
Offer builds a real interview for this exact role at AbbVie from your resume and this job description, asks the questions one at a time, and tells you what landed. The first one is free.
Practice this out loudThe full job description
As published by AbbVie.